CSMD
Congress SMid Growth ETF
CSMD is an actively managed fund that seeks long-term capital appreciation by investing in small- and mid-cap companies believed to be experiencing or will experience earnings growth.
US
EQUITY
Active
MANAGEMENT STYLE
$ 475.3 M
ASSETS UNDER MGMT
69 bp
EXPENSES
Fund Basics
| Inception date | Aug 22, 2023 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| HALOZYME THERAPEUTICS INC | 3.8 % |
| NVENT ELECTRIC PLC | 3.6 % |
| VALMONT INDUSTRIES | 3.4 % |
| RUBRIK INC-A | 3.3 % |
| REPLIGEN CORP | 3.3 % |
| CURTISS-WRIGHT CORP | 3.3 % |
| CARPENTER TECHNOLOGY | 3.2 % |
| UFP TECHNOLOGIES INC | 2.9 % |
| MEDPACE HOLDINGS, INC. | 2.8 % |
| SAMSARA, INC. CLASS A | 2.7 % |
Constituent Breakdown
| Number of holdings | 46 |
| Herfindahl-Hirschman Index | 246 |
| Wgt avg mkt cap (mns) | $12,381 |
| Large cap (>$10bn) | 51.5% |
| Mid cap ($2-10bn) | 47.8% |
| Small cap (<$2bn) | 0.0% |
| Developed mkts. | 99.3% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 94.0 % |
 |
BRITAIN | 3.6 % |
 |
IRELAND | 2.2 % |
Historical Performance
Standardized Performance (as of 08/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 8.3% | 5.1% | 7.5% | 9.6% | -- | -- | -- | 10.9% |
| Dividend Yield | 0.0% | 0.0% | 0.2% | 0.1% | -- | -- | -- | 0.1% |
| Total Returns | 8.3% | 5.1% | 7.7% | 9.8% | -- | -- | -- | 11.0% | Ann. Volatility | 22.1% | 21.2% | 21.4% | 20.1% | -- | -- | -- | 20.1% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.35 | 66% |
| MSCI EAFE | 0.98 | 52% |
| MSCI Emg Mkts | 0.62 | 53% |
Liquidity Measures
| Avg. volume (000) | 45 |
| ADV traded (mns) | $2 |
| Turnover | 0.3% |
| Avg. Bid/Ask (% of price) | 0.18% |
Technical Indicators
| 30d moving avg. (EMA) | $35.07 |
| Relative strength (RSI) | 58 |
| MACD/Signal | 0.43/0.20 |
| Bollinger Bands (Upper/Lower) | $36.89/$32.69 |
| Short interest (% of AUM) | 0.3% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. CSMD |
Expenses vs. CSMD |
ALTAR Score™ vs. CSMD |
|---|---|---|---|---|
| RFG | Invesco S&P Midcap 400 Pure Growth ETF | 17.2% | -34 bp | +1.6% |
| MCOW | Pacer S&P MidCap 400 Quality FCF Aristocrats ETF | 14.5% | -20 bp | +3.0% |
| XMMO | Invesco S&P MidCap Momentum ETF | 14.5% | -35 bp | +0.3% |
| GRPM | Invesco S&P MidCap 400 GARP ETF | 13.9% | -34 bp | +2.9% |
| XMHQ | Invesco S&P MidCap Quality ETF | 12.5% | -44 bp | +2.6% |
| RSMC | Rockefeller U.S. Small-Mid Cap ETF | 12.4% | +6 bp | +0.7% |
| RNSC | Furst Trust Small Cap US Equity Select ETF | 12.1% | -9 bp | +1.5% |
| GRNJ | Fundstrat Granny Shots US Small & Mid Cap ETF | 12.0% | +6 bp | -1.7% |
| FFOX | FundX Future Fund Opportunities ETF | 11.8% | +31 bp | -0.6% |
| FSGS | First Trust SMID Growth Strength ETF | 11.3% | -9 bp | +1.6% |
Risk and Returns: CSMD vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 9/6/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
4.3%
ALTAR SCORE™
31st
PERCENTILE
UNDERWEIGHT
ETFRC RATING
There are 1,408 funds in the US Equity category with an average
ALTAR Score™ of 5.2% and a standard deviation
of 2.0%. CSMD's ALTAR Score™ is approximately -0.5 standard
deviations above the category average. This places CSMD in the 31st percentile
among funds in the category.
Sell-Side Consensus
$40.43
PRICE TARGET
+18.0%
UPSIDE